Medications for Myasthenia Gravis Generalized

5 results

  • bkemv

    (eculizumab-aeeb)
    Amgen Inc
    BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive.

  • rystiggo

    (ROZANOLIXIZUMAB)
    UCB, Inc.
    RYSTIGGO is indicated for treating generalized myasthenia gravis (gMG) in adult patients who test positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

  • soliris

    (ECULIZUMAB)
    Alexion Pharmaceuticals Inc.
    SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.

  • ultomiris

    (ravulizumab)
    Alexion Pharmaceuticals Inc.
    ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.

  • vyvgart

    (EFGARTIGIMOD ALFA)
    argenx US
    VYVGART is indicated for treating generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.